Betadex sulfobutyl ether sodium 182410-00-0

Category:Intermediates > Chiral Intermediates
Product Name:Betadex sulfobutyl ether sodium 182410-00-0
CAS No.:182410-00-0
Standard:USP
Price(USD):0.00
Company:Shandong Binzhou Zhiyuan Biotechnology Co., Ltd.

Basic Info
  • Grade: Injection Grade

    Factory Location: Binzhou

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe

  • Monthly Production Capacity: 5000kg

    Packaging Information: 500g/bag , 1kg/bag, 10kg/drum , 20kg/drum or customized

  • Delivery Lead Time: Within one week

    Sample Provided: yes

    Payment Terms: T/T

    Basic information

     

    Name: Betadex sulfobutyl ether sodium 

    CAS: 182410-00-0

    Molecular formula :C42H70-nO35 (C4H8O3S Na)n

    Molecular weight: 1135+158n

    Qaulity : Injection grade  

    Standard : USP41

    Package: 500g/bag , 1kg/bag,  10kg/drum , 20kg/drum or customized

     

    The role in ophthalmic medicine

    Betadex sulfobutyl ether sodium has little stimulation on cornea and can reduce the irritation of drugs on the eyeball, so it is very suitable for the preparation of eye drops with physiological pH and osmotic pressure requirements.

    Ganciclovir was soluble in water, but the water solubility was significantly affected by pH, more easily in dissolved under acidic conditions. The pH and osmotic pressure of the eyedrops are strictly required. The results showed that the Betadex sulfobutyl ether sodium in the prescription significantly reduced the eye irritation of ganciclovir, and the inclusion of Betadex sulfobutyl ether sodium on the drug could increase the biocompatibility of the eye drops.

    O,O’-Dipropionyl-(1,4-xylylene)bispilocarpate is a precursor of trabeculin, a drug for glaucoma treatment. It has a strong irritation to the eye and affects its clinical application. After adding Betadex sulfobutyl ether sodium to the prescription of the eye drops, it was found that the irritation of Betadex sulfobutyl ether sodium eye drops to rabbit eyes was significantly reduced within the range of 24 ~ 36mmol. L-1. The mechanism may be that when the drug forms a inclusion compound with Betadex sulfobutyl ether sodium, the inclusion compound can slowly release the drug in the eye, so as to reduce the local concentration of the free drug and reduce or eliminate the eye irritation caused by the rapid absorption or precipitation of the drug.

     

     

Send your message to this supplier
  • From:
  • To:
    Shandong Binzhou Zhiyuan Biotechnology Co., Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service